Showing 761-770 of 9295 results for "".
Considerations for the Use of Biologics in Children with Atopic Dermatitis
https://practicaldermatology.com/series/dermatology-hub-neuroimmune-network/derm-hub/37152/Dawn Zhang Eichenfield, MD, PhD, a dermatologist at Rady Children's Hospital-San Diego and an assistant clinical professor of dermatology at the University of California, San Diego, School of Medicine, explains the most important factors to understand when prescribing biologics for pediatric atopicISDPA: Dr. Dy on JAK Inhibitors for Alopecia Areata
https://practicaldermatology.com/conferences/isdpa-midwest-derm-2024/isdpa-dr-dy-jak-inhibitors-alopecia-areata/29150/Lady Dy, MD, talks about the efficacy and safety of JAK inhibitors for treating alopecia areata at the Illinois Society of Dermatology Physician Assistants (ISDPA) Midwest Dermatology Conference 2024.DermWireTV: Diagnosing Melanoma Using Deep-Learning Model; New Adbry Approval
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-diagnosing-melanoma-using-deep-learning-model-new-adbry-approval/26445/In this week's DermWireTV, researchers develop a novel deep-learning model designed to more accurately diagnose melanoma; LEO Pharma receives a new approval for atopic dermatitis drug Adbry; and in our PA Perspectives segment, Andrew Mastro discusses how to build an inflammatory clinic.Reducing Atopic March Risk in Pediatric Atopic Dermatitis
https://practicaldermatology.com/programs/practical-dermatology-type-ii-inflammation-journal-club/reducing-atopic-march-risk-in-pediatric-atopic-dermatitis/54821/Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, is joined by Editorial Board member Peter Lio, MD, to analyze the Journal of the American Academy of Dermatology article "Reduced atopic march risk in pediatric atopic dermatitis patients prescribed dupilumab versus cAdvocacy and Research
https://practicaldermatology.com/series/the-practical-dermatology-podcast/advocacy-and-research/36479/The latest news and updates, plus Harrison Nguyen, MD, MBA, MPH, FAAD, discusses addressing barriers to maximizing biologics for psoriasis, and Mark Lebwohl, MD, FAAD, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to talk about some of the latest research he has been involvDr. Simpson Highlights Potentially Remittive Anti-OX40s at Maui Derm
https://reachmd.com/programs/practical-dermatology/dr-simpson-highlights-potentially-remittive-anti-ox40s-at-maui-derm/32920/Two anti-OX40 drugs in the pipeline may have remittive properties for atopic dermatitis, according to Eric Simpson, MD.SDPA: Dr. Matthew Zirwas Discusses Benefits of Attending the Annual Conference
https://practicaldermatology.com/conferences/sdpa-2024/sdpa-dr-matthew-zirwas-discusses-benefits-of-attending-the-annual-conference/29510/At the SDPA 22nd Annual Fall Dermatology Conference, Practical Dermatology caught up with Matthew Zirwas, MD. Dr. Zirwas shares why he looks forward to lecturing at the annual meeting.SDPA: Medical Director Dr. Hilary Baldwin Discusses Acne and Keloids Lectures
https://practicaldermatology.com/conferences/sdpa-2024/sdpa-medical-director-dr-hilary-baldwin-discusses-acne-and-keloids-lectures/29508/At the SDPA 22nd Annual Fall Dermatology Conference, Practical Dermatology caught up with conference medical director Hilary Baldwin, MD. She explains the key takeaways of her lectures on acne and keloids.FDA Approves Bimzelx for Hidradenitis Suppurativa
https://practicaldermatology.com/series/dermwire-tv/fda-approves-bimzelx-hidradenitis-suppurativa/29518/In this week's DermwireTV, the FDA approves a new treatment for moderate to severe hidradenitis suppurativa; the FDA agrees to review the resubmission of Dupixent for the treatment of CSU; and the president of Merz Aesthetics, North America, joins us to discuss trends in the aesthetic market.FDA Approves Rosacea Treatment Emrosi
https://practicaldermatology.com/series/dermwire-tv/fda-approves-rosacea-treatment-emrosi/29207/In this week's DermwireTV, the FDA approves a first-of-its-kind treatment for rosacea in adults; two companies with approved atopic dermatitis products provide new long-term efficacy and safety data; and Andrew Mastro discusses how to recognize physician burnout.